Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lantern Pharma Inc.

< Previous 1 2 3 Next >
News headline image
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
News headline image
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.